Assembly BiosciencesASMB +10.25%32 EBITDA Margin % is -138.12% as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 944 Biotechnology companies, Assembly Biosciences ranks better than 59.64% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Assembly Biosciences EBITDA Margin % Related Terms
Assembly Biosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASMB vs MDXG, AGMB, TRAX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Assembly Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences (ASMB) has a EBITDA Margin % of -138.12% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Assembly Biosciences and its competitors. According to the industry distribution chart, Assembly Biosciences ranks #381 out of 944 companies in the Biotechnology industry, placing it in the top 40.4%.
Is Assembly Biosciences' EBITDA Margin % too high?
Assembly Biosciences' current EBITDA Margin % is -138.12%. Based on the distribution chart, Assembly Biosciences ranks #381 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Assembly Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' EBITDA Margin % compare to MDXG and AGMB?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #381 out of 944 companies for EBITDA Margin %. This puts Assembly Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current EBITDA Margin % is -138.12%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current EBITDA Margin % of -138.12%. The current EBITDA Margin % is -138.12%. Assembly Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current EBITDA Margin % is -138.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
32GF Score
Get the complete analysis for ASMB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
